Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Comparison of general clinical data between the mild calcification and moderate to severe calcification groups in MHD patientsVariablesMild-calcification group (n = 41)Moderate to severecalcification group (n = 45) t/Z/X 2 P Gender0.3480.055Male, n (%)28(68.29)28(62.22%)Female, n(%)13(31.71)17(37.78)Age (year)58.61 ± 12.8760.56 ± 10.05-0.7850.435BMI (kg/m2)22.24 ± 3.2622.89 ± 2.900.5230.603Hemodialysis duration (months)38(38)33(49.5)-1.4750.140Smoking, n(%)24(58.54)18(40.00)2.9500.086Drinking, n(%)21(51.22)15(33.33))2.8200.093Hypertension, n(%)39(95.12)45(100.00)2.2470.224Diabetes mellitus, n(%)15(36.56)25(55.56)3.1030.078Hyperlipidemia, n(%)10(24.39)18(33.33)2.3810.123Osteoporosis, n(%)6(14.63)15(17.78)0.1560.693Alb (g/L)39.53 ± 2.5738.98 ± 3.02-0.9080.366TG (mmol/L)1.52(1.95)1.65(1.93)-0.2380.812TC (mmol/L)3.70 ± 1.153.97 ± 0.76-1.2600.212HDL-C (mmol/L)0.95(0.36)1.02(0.54)-0.9730.331LDL-C (mmol/L)1.73(1.3)2.28(0.82)-1.8370.066Glu (mmol/L)7.875.23)7.99(5.05)-0.1040.613Ca (mmol/L)2.19 ± 0.192.17 ± 0.150.6450.520P (mmol/L)1.68 ± 0.451.93 ± 0.52-2.3560.021Ca×P (mg2/dL2)45.61 ± 12.7051.73 ± 14.36-2.0860.040Mg (mmol/L)1.02 ± 0.161.03 ± 0.17-0.3330.740ALP (U/L)96.60(59.40)79.10(33.50)-2.0790.038CT (pg/mL)8.07(14.30)8.08(7.89)-0.0430.96525-(OH)D (ng/mL)12.96(6.95)13.80(8.31)-0.5970.551iPTH (pg/mL)483.99(400.28)287.09(300.02)-2.7500.006tPINP (ng/mL)343.80(329.30)237.00(169.40)-3.3490.001 N-MID OC (ng/mL)163.70(69.15)102.20(102.11)-3.4110.001β-CTX (pg/mL)2293(1575.5)1508(1190)-2.9570.003Abbreviation: BMI body mass index, Alb albumin, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Glu glucose, Ca calcium, P phosphate, Ca×P the product of calcium and phosphorus, Mg magnesium, ALP alkaline phosphatase, CT calcitonin, 25-(OH)D 25-hydroxy vitamin D, iPTH intact parathyroid hormone, tPINP total type I procollagen amino-terminal peptide, N-MID OC N-terminal mid-fragment of osteocalcin, β-CTX β-Type I collagen crosslinked carboxyl-terminal peptide

Source: Comparison of general clinical data and laboratory examination indicators. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 123 patients were enrolled.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The relationship between coronary artery calcification and bone metabolic markers in maintenance hemodialysis patients

Study design awaiting verification · BMC Nephrology · 2023

Original publication title

The relationship between coronary artery calcification and bone metabolic markers in maintenance hemodialysis patients

Lin Xiong; Qi-qi Chen; Yong Cheng; Yong-shu Lan; Jian-bo Yang; Xiang-qiong Wen; Xin Xie; Ting Kang; Wei-hua Wu; Santao Ou

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Elevated serum P and Ca×P were independent risk factors for CAC in MHD patients, and serum Mg may be an independent protective factor for CAC. CAC was closely related to abnormal bone metabolism and bone metabolic markers in MHD patients. Relatively low bone turnover can promote the occurrence and development of CAC. N-MID OC may be a reliable bone metabolic marker linking vascular calcification and bone metabolism in MHD patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

To study the influencing factors for coronary artery calcification (CAC) in maintenance hemodialysis (MHD) patients and the relationship between CAC and bone metabolism markers and to attempt to find a reliable marker linking vascular calcification and bone metabolism in MHD patients.

Source: Background

Abstract: What methods does the paper describe?

A total of 123 patients were enrolled. CAC was assessed by multislice spiral computed tomography (MSCT), and the CAC score (CACS) was evaluated using the Agaston method. Routine laboratory parameters, including triglycerides (TG), total cholesterol (TC), glucose (Glu), calcium (Ca), phosphorus (P), magnesium (Mg), etc., were measured. Serum markers of bone metabolism, such as alkaline phosphatase(ALP), calcitonin (CT), 25-hydroxy vitamin D [25-(OH)D], intact parathyroid hormone (iPTH), total type I procollagen amino-terminal peptide (tPINP), N-terminal mid-fragment of osteocalcin (N-MID OC), and β-type I collagen crosslinked carboxyl-terminal peptide (β-CTX), were also measured.

Source: Methods

Abstract: Results

Among 123 MHD patients, 37 patients (30.08%) did not have CAC, and 86 patients (69.92%) had CAC, including 41 patients (47.67%) with mild calcification and 45 patients (52.33%) with moderate to severe calcification. Age, Body Mass Index(BMI), the prevalence of hypertension and diabetes mellitus, TC, Glu, P, and Ca×P in the calcification group were higher than those in the noncalcification group, whereas Mg, iPTH, tPINP, N-MID OC, and β-CTX were lower than those in the noncalcified group (P < 0.05).

Compared with the mild calcification group (0<CACS<400), P and Ca×P levels were higher in the moderate to severe calcification group (CACS ≥ 400), and ALP, iPTH, N-MID OC, tPINP, and β-CTX concentrations were lower (P < 0.05). Correlation analysis showed that the CACS was positively correlated with TC, LDL-C, P, and Ca×P (P < 0.05) and negatively correlated with N-MID OC and β-CTX (P < 0.05). There was no significant correlation between the CACS and other parameters (P > 0.05).

A logistic regression model was used to evaluate the influencing factors for CAC. The results showed that age, BMI, TC, Glu, P, and Ca×P were risk factors for CAC and its severity in MHD patients, whereas diabetes mellitus, Mg, and N-MID OC were protective factors for CAC in MHD patients. In addition, N-MID OC was a protective factor for the severity of CAC. After adjusting for the corresponding confounding factors, the results of the risk factors were consistent, and N-MID OC was still an independent protective factor for CAC and its severity.

Source: Results

Abstract: Conclusions

Elevated serum P and Ca×P were independent risk factors for CAC in MHD patients, and serum Mg may be an independent protective factor for CAC. CAC was closely related to abnormal bone metabolism and bone metabolic markers in MHD patients. Relatively low bone turnover can promote the occurrence and development of CAC. N-MID OC may be a reliable bone metabolic marker linking vascular calcification and bone metabolism in MHD patients.

Source: Conclusions
Authors’ abstract

Background

To study the influencing factors for coronary artery calcification (CAC) in maintenance hemodialysis (MHD) patients and the relationship between CAC and bone metabolism markers and to attempt to find a reliable marker linking vascular calcification and bone metabolism in MHD patients.

Methods

A total of 123 patients were enrolled. CAC was assessed by multislice spiral computed tomography (MSCT), and the CAC score (CACS) was evaluated using the Agaston method. Routine laboratory parameters, including triglycerides (TG), total cholesterol (TC), glucose (Glu), calcium (Ca), phosphorus (P), magnesium (Mg), etc., were measured. Serum markers of bone metabolism, such as alkaline phosphatase(ALP), calcitonin (CT), 25-hydroxy vitamin D [25-(OH)D], intact parathyroid hormone (iPTH), total type I procollagen amino-terminal peptide (tPINP), N-terminal mid-fragment of osteocalcin (N-MID OC), and β-type I collagen crosslinked carboxyl-terminal peptide (β-CTX), were also measured.

Results

Among 123 MHD patients, 37 patients (30.08%) did not have CAC, and 86 patients (69.92%) had CAC, including 41 patients (47.67%) with mild calcification and 45 patients (52.33%) with moderate to severe calcification. Age, Body Mass Index(BMI), the prevalence of hypertension and diabetes mellitus, TC, Glu, P, and Ca×P in the calcification group were higher than those in the noncalcification group, whereas Mg, iPTH, tPINP, N-MID OC, and β-CTX were lower than those in the noncalcified group (P < 0.05).

Compared with the mild calcification group (0<CACS<400), P and Ca×P levels were higher in the moderate to severe calcification group (CACS ≥ 400), and ALP, iPTH, N-MID OC, tPINP, and β-CTX concentrations were lower (P < 0.05). Correlation analysis showed that the CACS was positively correlated with TC, LDL-C, P, and Ca×P (P < 0.05) and negatively correlated with N-MID OC and β-CTX (P < 0.05). There was no significant correlation between the CACS and other parameters (P > 0.05).

A logistic regression model was used to evaluate the influencing factors for CAC. The results showed that age, BMI, TC, Glu, P, and Ca×P were risk factors for CAC and its severity in MHD patients, whereas diabetes mellitus, Mg, and N-MID OC were protective factors for CAC in MHD patients. In addition, N-MID OC was a protective factor for the severity of CAC. After adjusting for the corresponding confounding factors, the results of the risk factors were consistent, and N-MID OC was still an independent protective factor for CAC and its severity.

Conclusions

Elevated serum P and Ca×P were independent risk factors for CAC in MHD patients, and serum Mg may be an independent protective factor for CAC. CAC was closely related to abnormal bone metabolism and bone metabolic markers in MHD patients. Relatively low bone turnover can promote the occurrence and development of CAC. N-MID OC may be a reliable bone metabolic marker linking vascular calcification and bone metabolism in MHD patients.

Publication and source details

Original title: The relationship between coronary artery calcification and bone metabolic markers in maintenance hemodialysis patients

Lin Xiong; Qi-qi Chen; Yong Cheng; Yong-shu Lan; Jian-bo Yang; Xiang-qiong Wen; Xin Xie; Ting Kang; Wei-hua Wu; Santao Ou

BMC Nephrology · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan ProvinceHYX20010.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:21:12.560763+00:00

DOI: 10.1186/s12882-023-03286-z · PMC10428586